E-LIB Suche - Ergebnisse für: Sharp, Cierra N.

1

Neutral ceramidase deficiency protects against cisplatin-in..:

Sears, Sophia M. ; Dupre, Tess V. ; Shah, Parag P....
Journal of Lipid Research. 63 (2022) 3 - p. 100179 , 2022

2

A Shared Diagnostic Stewardship Approach toward Improving A..:

Sharp, Cierra N ; Fletcher, Anita ; Muluhngwi, Penn...
The Journal of Applied Laboratory Medicine. 6 (2020) 2 - p. 387-396 , 2020

Link: https://doi.org/10.1093/..

3

ELISA-based detection of Open Reading Frame protein 1 in pa..:

Sharp, Cierra N. ; Korte, Erik A. ; Hosseinejad, Keivan...
Clinica Chimica Acta. 507 (2020) - p. 1-6 , 2020

Link: https://doi.org/10.1016/..

4

Verification of Newly FDA-Approved Kappa and Lambda Free Li..:

Muluhngwi, Penn ; Sharp, Cierra N. ; Pozzi, Nicole..
The Journal of Applied Laboratory Medicine. 4 (2019) 3 - p. 323-330 , 2019

Link: https://doi.org/10.1373/..

5

Long interspersed nuclear element-1 mobilization as a targe..:

Lavasanifar, Afsaneh ; Sharp, Cierra N. ; Korte, Erik A....
Clinica Chimica Acta. 493 (2019) - p. 52-62 , 2019

Link: https://doi.org/10.1016/..

6

Cisplatin Effects in Lung Adenocarcinoma-bearing Mice, Alon..:

Sharp, Cierra N.
Toxicologic Pathology. 46 (2018) 8 - p. 1049-1050 , 2018

Link: https://doi.org/10.1177/..

7

Inhibiting glucosylceramide synthase exacerbates cisplatin-..:

Dupre, Tess V. ; Doll, Mark A. ; Shah, Parag P....
Journal of Lipid Research. 58 (2017) 7 - p. 1439-1452 , 2017

Link: https://doi.org/10.1194/..

8

Neutral ceramidase deficiency protects against cisplatin-in..:

Sears, Sophia M ; Dupre, Tess V ; Shah, Parag P...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8953688/. , 2022

Link: http://www.ncbi.nlm.nih...

9

C57BL/6 mice require a higher dose of cisplatin to induce r..:

Sears, Sophia M ; Sharp, Cierra N ; Krueger, Austin...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7642885/. , 2020

Link: http://www.ncbi.nlm.nih...

10

Polypharmacy: A Healthcare Conundrum with a Pharmacogenetic..:

Sharp, Cierra N ; Linder, Mark W ; Valdes, Roland
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7195220/. , 2019

Link: http://www.ncbi.nlm.nih...

11

Moderate aging does not exacerbate cisplatin-induced kidney..:

Sharp, Cierra N ; Doll, Mark ; Dupre, Tess V..
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6383196/. , 2019

Link: http://www.ncbi.nlm.nih...

12

Subclinical kidney injury induced by repeated cisplatin adm..:

Sharp, Cierra N ; Doll, Mark A ; Megyesi, Judit...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6087791/. , 2018

Link: http://www.ncbi.nlm.nih...

13

Inhibiting glucosylceramide synthase exacerbates cisplatin-..:

Dupre, Tess V ; Doll, Mark A ; Shah, Parag P...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5496040/. , 2017

Link: http://www.ncbi.nlm.nih...

14

Developing better mouse models to study cisplatin-induced k..:

Sharp, Cierra N ; Siskind, Leah J
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5668582/. , 2017

Link: http://www.ncbi.nlm.nih...

15

Repeated administration of low-dose cisplatin in mice induc..:

Sharp, Cierra N ; Doll, Mark A ; Dupre, Tess V...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4796272/. , 2016

Link: http://www.ncbi.nlm.nih...